Cargando…

The Role of Glucocorticoids in the Management of COVID-19

Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexaki, Vasileia Ismini, Henneicke, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781662/
https://www.ncbi.nlm.nih.gov/pubmed/33207372
http://dx.doi.org/10.1055/a-1300-2550
_version_ 1783631721857548288
author Alexaki, Vasileia Ismini
Henneicke, Holger
author_facet Alexaki, Vasileia Ismini
Henneicke, Holger
author_sort Alexaki, Vasileia Ismini
collection PubMed
description Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19.
format Online
Article
Text
id pubmed-7781662
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-77816622021-01-06 The Role of Glucocorticoids in the Management of COVID-19 Alexaki, Vasileia Ismini Henneicke, Holger Horm Metab Res Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19. Georg Thieme Verlag KG 2021-01 2020-11-18 /pmc/articles/PMC7781662/ /pubmed/33207372 http://dx.doi.org/10.1055/a-1300-2550 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Alexaki, Vasileia Ismini
Henneicke, Holger
The Role of Glucocorticoids in the Management of COVID-19
title The Role of Glucocorticoids in the Management of COVID-19
title_full The Role of Glucocorticoids in the Management of COVID-19
title_fullStr The Role of Glucocorticoids in the Management of COVID-19
title_full_unstemmed The Role of Glucocorticoids in the Management of COVID-19
title_short The Role of Glucocorticoids in the Management of COVID-19
title_sort role of glucocorticoids in the management of covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781662/
https://www.ncbi.nlm.nih.gov/pubmed/33207372
http://dx.doi.org/10.1055/a-1300-2550
work_keys_str_mv AT alexakivasileiaismini theroleofglucocorticoidsinthemanagementofcovid19
AT henneickeholger theroleofglucocorticoidsinthemanagementofcovid19
AT alexakivasileiaismini roleofglucocorticoidsinthemanagementofcovid19
AT henneickeholger roleofglucocorticoidsinthemanagementofcovid19